Buy your textbooks here

Free 920-130 Text Books of Killexams.com | study guide | Braindumps | Study Guides | Textbook

Fastest training and knowledge source is Killexams.com PDF Questions and Answers and exam simulator that uses 920-130 VCE - examcollection - braindumps to make best test prep combination - study guide - Study Guides | Textbook

Pass4sure 920-130 dumps | Killexams.com 920-130 actual questions | https://www.textbookw.com/


Killexams.com 920-130 Dumps and actual Questions

100% actual Questions - Exam Pass Guarantee with high Marks - Just Memorize the Answers



920-130 exam Dumps Source : Symposium Express convoke Center

Test Code : 920-130
Test appellation : Symposium Express convoke Center
Vendor appellation : Nortel
: 57 actual Questions

where must I badge in for 920-130 exam?
I commenced virtually considering 920-130 exam simply when you explored me approximately it, and now, having chosen it, I sense that I accommodate settled at the proper preference. I handed examination with exclusive opinions utilising killexams.Com Dumps of 920-130 examination and got 89% marks which is very qualified for me. In the wake of passing 920-130 exam, I accommodate numerous openings for labor now. Much liked killexams.Com Dumps for assisting me evolution my vocation. You shaked the beer!


Got no problem! 3 days preparation of 920-130 actual test questions is required.
It is not the primary time i am using killexamsfor my 920-130 exam, i accommodate attempted their materials for some vendors examinations, and havent failed as soon as. I absolutely reckon on this steering. This time, I additionally had some technical problems with my pc, so I had to handle their customer advocate to double test some thing. Theyve been top notch and accommodate helped me benign matters out, in spite of the fact that the problem become on my prevent, not their software program program.


can you disagree with that every one 920-130 questions I had accommodate been requested in actual check.
hi! im julia from spain. exigency to bypass the 920-130 exam. however. My English may exist very bad. The language is effortless and lines are quick . No worry in mugging. It helped me wrap up the guidance in 3 weeks and i surpassed wilh 88% marks. now not capable of crack the books. lengthy strains and difficult words accomplish me sleepy. needed an immaculate manual badly and finally observed one with the killexams.com mind dumps. I were given every sole query and reply . first rate, killexams! You made my day.


Dumps today's 920-130 exam are to exist had now.
I will hint you to Come birthright here to remove every sole fears related to 920-130 certification due to the fact this is a wonderful platform to tender you with confident goods for your preparations. I became involved for 920-130 examination but every sole course to killexams.Com who supplied me with tremendous products for my coaching. I become actually involved approximately my success however it changed into best 920-130 exam engine that increased my achievement self credence and now I am emotion satisfaction in this unconditional assist. Hats off to you and your incredible services for every sole college students and professionals!


Did you attempted this exceptional source of latest dumps.
Hi Team, I accommodate completed 920-130 in first attempt and thanks a lot for your useful question bank.


actual retract a view at questions of 920-130 exam are to exist had now.
in case you exigency proper 920-130 schooling on how it works and what are the assessments and every sole then dont blow it unhurried and opt for killexams.com as its miles an closing supply of assist. I additionally wanted 920-130 education and i even opted for this super check engine and were given myself the first-class education ever. It guided me with each thing of 920-130 examand provided the pleasant questions and solutions i accommodate ever visible. The retract a view at courses additionally were of very much help.


Do no longer blow some time on looking, simply glean the ones 920-130 Questions from actual test.
i accommodate advised about your gadgets to numerous partners and companions, and theyre every sole extraordinarily fulfilled. a mighty deal obliged killexams.com Questions & solutions for boosting up my career and helping me diagram nicely for my excessiveexams. a whole lot preferred over again. I exigency to whisper that i am your greatest fan! I want you to recognize that I cleared my 920-130 exam these days, deliberating the 920-130 route notes i purchased from you. I solved 86/95 questions within theexam. you are the character training company.


proper here is proper supply brand newmodern dumps, reform solutions.
I had taken the 920-130 instruction from the killexams.Com as that modified into a nice platform for the training and that had ultimately given me the fine degree of the steerage to glean the splendid scores inside the 920-130 retract a glance atchecks. I simply loved the manner I got the topics completed within the thoughtprovoking manner and through the serve of the identical; I had in the long dash had been given the detail on the line. It had made my guidance a qualified buy less knotty and with the serve of the killexams.Com I were capable of develop well within the existence.


I sense very assured with 920-130 exam bank.
that is an without a doubt cogent and dependable resource, with actual 920-130 questions and accurate answers. The checking out engine works very smooth. With extra info and suitable customer support, this is an incredibly desirable provide. No free random braindumps available on line can examine with the fine and the coolest luxuriate in I had with Killexams. I exceeded with a virtually exorbitant score, so Im telling this primarily based on my private experience.


Very tough 920-130 examination questions asked within the examination.
killexams.Com is the most nice course i accommodate ever lengthy beyond over to glean geared up and skip IT checks. I desiremore people thought approximately it. But then, there is probably greater risks someone must close it down. The constituent is, it provides for the very problem what I should apprehend for an examination. Whats more I stand for various IT assessments, 920-130 with 88% marks. My companion utilized killexams.Com for lots special certificates, every sole terrific and big. In reality stable, my individual top alternatives.


Nortel Nortel Symposium Express Call

VoIP certification tracks - Nortel's advocate certifications | killexams.com actual Questions and Pass4sure dumps

As outlined in a previous tip, agencies are enforcing IP telephony greater commonly on their information infrastructures. The increased deployment has created a necessity for certified IP telephony engineers to provide proven, most reliable-of-breed expertise.

The IP telephony certifications Nortel presently offers are divided into 4 categories: serve expert, Design specialist, aid professional, and Design expert. This tip discusses the Nortel advocate music.

support professional

The serve expert certifications are intended to pomp an individual's aptitude to implement, function, and troubleshoot a Nortel Networks IP Telephony solution. The assist professional certification displays a candidate with three to six months of sustain that can tackle pursuits technical concerns of a typical Nortel IP Telephony solution.

NNCSS - VoIP Succession BCM three.0

This certification exams the aptitude to enforce, function, and troubleshoot the enterprise Communications supervisor three.0. This certification covers hardware, delivery-up, records and voice networking, functions, and troubleshooting the BCM. To pass the certification, two exams accommodate to exist successfully accomplished: expertise specifications and Protocols for IP Telephony options, and Succession BCM three.0. The know-how necessities and Protocols for IP Telephony options examination is an overview of convergence technologies.

NNCSS - CallPilot Rls. 2.0

This certification tests the skill to enforce, function, and troubleshoot the VoIP CallPilot 2.0. This certification covers hardware, administration, interoperability with Meridian 1 switches, and safety of a sole web page CallPilot equipment. To flood the certification, two checks must exist efficaciously completed: Meridian Database and CallPilot 2.0.

NNCSS - Symposium convoke middle Server or Symposium convoke middle Server setting up and upkeep

These two certifications test the means to enforce, operate, and troubleshoot the Symposium convoke core Server. both certifications cover hardware, application setting up, administration, and upkeep of Symposium appellation middle Server four.2, Symposium web client 4.0, and Symposium express three.0. despite the fact, the Symposium convoke headquarters Server certification besides checks the structure, customized configuration and integration of the server. To circulate both of these certifications, one exam should exist successfully completed: Symposium convoke middle or Symposium appellation middle installing and upkeep, respectively.

NNCSS - Symposium convoke headquarters TAPI/Agent or appellation headquarters TAPI/Agent installing and protection

These two certifications view at various the aptitude to enforce, operate, and troubleshoot the Symposium appellation core TAPI/Agent. each certifications cowl hardware, utility setting up, administration, and protection of Symposium TAPI 2.three and Symposium Agent 2.three. despite the fact, the Symposium convoke middle TAPI/Agent certification besides exams the architecture, integration, and customized configuration of the TAPI/Agent. To slump either of these certifications, one exam exigency to exist efficaciously achieved: Symposium appellation middle TAPI/Agent or Symposium appellation middle TAPI/Agent Inst/leading, respectively.

NNCSS - Symposium express appellation headquarters or Symposium express convoke headquarters installing and protection

These certifications examine the capability to set aside in force, function, and troubleshoot the Symposium express appellation middle. both certifications cover hardware, application installation, administration, and maintenance of Symposium categorical convoke middle four.2. despite the fact, the Symposium express convoke middle certification besides exams the structure and integration of the appellation middle. To circulate either of the certifications, one examination exigency to exist successfully accomplished: Symposium specific convoke middle or Symposium express appellation middle Inst and Maint respectively.

NNCSS - VoIP Multimedia communique Server (MCS) 5100 2.0

This certification tests the potential to enforce, function, and troubleshoot the VoIP Multimedia communique Server (MCS) 5100 2.0. This certification covers setting up of the hardware and software, configuration, maintenance, and administration of the Multimedia verbal exchange Server (MCS) 5100 2.0. To pass the certification, two exams should exist correctly completed: expertise standards and Protocols for IP Telephony solutions, and VoIP Multimedia communication Server (MCS) 5100 2.0. The technology requisites and Protocols for IP Telephony options examination is an overview of convergence applied sciences.

NNCSS - VoIP Succession a thousand/1000M Rls. 3.0 DB Administrator

This certification checks the means to preserve and troubleshoot the VoIP Succession a thousand/1000M Rls. 3.0 DB Administrator. This certification covers the structure, configuration, preservation, and administration of the Meridian 1, Succession one thousand Rls. 3.0, and Succession 1000M Rls. 3.0 the usage of fundamental Alternate Route selection (BARS) and network Alternate Route selection (NARS). To pass the certification, two tests exigency to exist efficaciously achieved: technology requisites and Protocols for IP Telephony options, and Succession 1000/1000M Rls. three.0 DB Administrator.

NNCSS - VoIP Succession one thousand/1000M Rls. 3.0 setting up and renovation

This certification assessments the capability to install, configure, and withhold the VoIP Succession one thousand/1000M Rls. three.0. This certification covers the setting up, architecture, configuration, preservation, and management of the Meridian 1, Succession one thousand Rls. three.0, and Succession 1000M Rls. three.0, web Telephones i2xxx, and Optivity Telephony supervisor (OTM) 2.1. To flood the certification, three exams must exist efficaciously accomplished: expertise requisites and Protocols for IP Telephony solutions, and Succession a thousand/1000M Rls. three.0 for Technicians, and Succession a thousand/1000M Rls. three.0.

help expert

The aid expert certifications build on the specialist's potential with the aid of demonstrating their skill to set aside into effect, operate, and troubleshoot an superior Nortel Networks IP Telephony solution. The assist knowledgeable certifications replicate a candidate with six to 12 months of arms-on event with the potential to lead or advocate intermediate-level personnel to maintain complicated Nortel IP Telephony solutions.

NNCSE - CallPilot 2.0 Unified Messaging solutions

This certification checks the aptitude to enforce, function, troubleshoot and optimize the VoIP CallPilot Unified Messaging reply 2.0. This certification covers the installation, administration, interoperability, safety, upgrade methods and accommodate usage for a multi web page CallPilot device. To flood the certification, the candidate exigency to first attain their NNCSS - CallPilot Rls. 2.0. because of this, the CallPilot 2.0 Unified Messaging solutions exigency to exist efficaciously accomplished to obtain this certification.

NNCSE - Contact center

This certification exams the capacity to implement, operate, troubleshoot and optimize the Contact core products. This certification covers the candidate's capabilities on the Symposium convoke headquarters Server (SCCS)/Symposium express convoke middle/Symposium internet client, Symposium TAPI carrier provider (TAPI SP), Symposium Agent, and the Symposium internet headquarters Portal. To flood the certification, the candidate should first achieve their NNCSS - Symposium convoke headquarters Server and the NNCSS - Symposium convoke middle TAPI/Agent certification. because of this, the Contact middle examination should exist effectively completed to gain this certification.

NNCSE - IP Convergence Succession one thousand/1000M Rls. 3.0

This certification assessments the aptitude to deploy, configure, hold, and optimize the VoIP Succession one thousand/1000M Rls. three.0. This certification covers the configuration, succession department workplace (BO), far flung workplace, operation, and Meridian 1 to Succession 1000M three.0 migration processes for the Succession 1000/1000M Rls. three.0, internet Telephones i2xxx, far off office 91xx, and Optivity Telephony manager (OTM) 2.1. To circulate the certification, the candidate exigency to first attain their NNCSS - VoIP Succession CSE one thousand Rls. 2.0 or the VoIP Succession a thousand/1000M Rls. 3.0 installation & upkeep certification. because of this, an extra extra elaborate edition of the Succession 1000/1000M Rls. 3.0 exam must exist efficaciously achieved to garner this certification.

in the IT trade, certifications are a course to validate an individual's skills within a unique area. The above Nortel IP Telephony certifications are one of the most tools that may demonstrate the capabilities of an IP Telephony usher knowledgeable. These certifications couldn't replace years of business experience, but they achieve provide the basis to serve and exploit Nortel Voice over IP solutions.

The next tip will talk about Nortel's Design IP Telephony certification song.

Richard Parsons (CCIE#5719) is a manager of professional functions for Callisma Inc., a totally owned subsidiary of SBC. He has developed an excellent groundwork in networking ideas, advanced troubleshooting, and monitoring in areas such as optical, ATM, VoIP, routed, routing, and storage infrastructures. wealthy resides in Atlanta GA, and is a graduate of Clemson tuition. His historical past contains senior and fundamental consulting positions at overseas network functions, Lucent, and Callisma.


Nortel: Wall road Analysts unhappy With this autumn effects | killexams.com actual Questions and Pass4sure dumps

No result found, are trying fresh keyword!After the convention convoke the day gone by, americaSecurities sharply dropped its 2007/2008 revenue and EPS estimates in addition to its inventory target rate. americanow expects Nortel to accommodate salary of $eleven.forty nine-billion ...

Symon Communications joins Nortel pick Product program in EMEA | killexams.com actual Questions and Pass4sure dumps

LONDON--(business WIRE)--June 14, 2005--Symon Communications Ltd, a leading global company of actual-time communications solutions for the appellation centre business, has been chosen with the aid of Nortel (NYSE:NT)(TSX:NT) to exist a portion of its select Product software (SPP) in Europe, the headquarters East and Africa (EMEA).

The programme is the precise tier of Nortel's Developer software, which provides participants with the haphazard to multiply and bring leading-side customer solutions. Symon's selection changed into based on Nortel's analysis of Symon's marketing strategy in addition to consumer enter.

"This announcement is awfully vital for Symon and Nortel customers alike," talked about Nelson Smelker, UK managing director, Symon Communications. "The undeniable fact that Symon and their true-time products are being particularly informed by means of Nortel illustrates the self credence that the resellers and their customers accommodate in their products. Nortel is one in every of their closest partners and they trust that their inclusion on the select Product application in Europe demonstrates that they are a legitimate and committed partner, in for the long haul."

"we are at every sole times seeking to simplify the course they labor with their channel companions as a course to give selection and actual mighty overall options to their halt consumers," renowned Paul Templeton, vp, commercial enterprise options, EMEA, Nortel. "we are very excited to accommodate Symon Communications exist portion of the EMEA select Product software, a strategic initiative certainly designed to supply their valued clientele access to suggested third-celebration products by means of Nortel channel partners."

The opt for Product application makes it practicable for shrunk Nortel Resellers (CNRs) to order arrogate third-celebration products below particular terms and stipulations of sale that strategically complement the Nortel product portfolio and create vast value for its valued clientele. pick items are defined as Nortel's most extremely counseled third-birthday celebration items for a specific performance. products in Symon's award-profitable actual-time communications portfolio, which includes Symon commercial enterprise Server (SES), Symon Vista and Symon TargetVision, accommodate every sole been chosen as pick items by course of Nortel.

in addition, Symon's latest group of workers management solution, Symon group, has been given an Orderable compatible designation, allowing the reply to exist ordered direct by the employ of Nortel ordering techniques.

Symon has been a a hit registered member of Nortel's EMEA Developer program seeing that July 2004. Nortel's Developer program has labored with creative businesses that complement and lengthen its product portfolio for over twenty years. The Developer application formalizes these confederate relationships, featuring an exceptional partnering framework that promotes options with plenary compatibility between add-ons.

The Nortel Developer application has diverse levels of membership, starting from the entry degree, foundation tier, Open Developer, where builders profit entry to a number of rig to facilitate their evolution efforts, through to Developer associate stage, where Nortel actively markets the Developer accomplice items. one of the vital pre-requisites for Developer associate status is the successful completion of compatibility testing, which raises consumer self assurance in the built-in solution. ultimately, builders might besides graduate by course of invitation best to the pick Product program stage, which is the desirable tier of the Developer program. Nortel pick products are strategic building blocks for Nortel creative structure and assist in featuring purchasers with essentially the most advantageous and efficient reply for their conversation needs. For more information on every sole Nortel pick items, please talk over with www.nortel.com/select. For additional advice on the Developer application, please talk over with www.nortel.com/prd/dpp.

About Symon Communications

Symon Communications Ltd, primarily based in Beckenham, UK, produces pleasant utility and hardware solutions to collect, analyse, document and song real-time, mission-critical productiveness suggestions for contact centres and different business functions. This information contains company metrics, group of workers effectivity and operations indicators.

Symon Communications' award-profitable items encompass browser-based Symon neighborhood personnel management utility and Symon Vista statistics presentation tools, Symon TargetVision visual messaging methods, patented Symon NetLite II wallboards, Symon DeskView visual computer messaging and alerting utility and the Symon business Server statistics administration device.

installed in more than 6,000 centres global, greater than four million clients view Symon Communications' products day by day. clients consist of Kwik fit, American categorical, Eli Lilly, Deutsche Telekom and Royal Mail group.

Symon Communications Ltd. is a unconditionally owned subsidiary of Symon Communications Inc. based mostly out of Plano, Texas.

About Nortel

Nortel is a identified leader in supplying communications capabilities that boost the human adventure, ignite and power world commerce, and snug and protect the area's most notable tips. Serving both carrier company and commercial enterprise customers, Nortel supplies resourceful expertise options encompassing conclusion-to-conclusion broadband, Voice over IP, multimedia services and functions, and wireless broadband designed to advocate individuals decipher the realm's premier challenges. Nortel does company in additional than a hundred and fifty nations. For more information, talk over with Nortel on the web at www.nortel.com. For the latest Nortel news, hunt advice from www.nortel.com/information.

definite assistance covered during this press release is ahead-searching and is territory to essential risks and uncertainties. The consequences or events anticipated in these statements may additionally fluctuate materially from actual effects or pursuits. components which might cause outcomes or events to vary from existing expectations encompass, amongst different things: the outcomes of regulatory and criminal investigations and civil litigation actions related to Nortel's restatements and the repercussion any resulting legal judgments, settlements, penalties and costs could accommodate on Nortel's effects of operations, pecuniary condition and liquidity, and any linked competencies dilution of Nortel's typical shares; the findings of Nortel's independent evaluate and implementation of advised remedial measures; the influence of the unbiased overview with recognize to revenues for specific recognized transactions, which evaluate could accommodate a particular stress on the underlying conduct that ended in the prefatory focus of those revenues; the restatement or revisions of Nortel's previously announced or filed economic consequences and ensuing contaminated publicity; the actuality of fabric weaknesses in Nortel's internal manage over fiscal reporting and the conclusion of Nortel's administration and impartial auditor that Nortel's interior wield over monetary reporting is ineffective, which could continue to influence Nortel's potential to document its effects of operations and monetary situation precisely and in a well timed manner; the accommodate an consequence on of Nortel's and NNL's failure to well timed file their economic statements and linked fitful reviews, including Nortel's exigency of aptitude to access its shelf registration observation filed with the us Securities and alternate commission (SEC); ongoing SEC experiences, which may halt up in adjustments to Nortel's and NNL's public filings; the influence of management changes, together with the termination for understanding behind Nortel's former CEO, CFO and Controller in April 2004; the sufficiency of Nortel's restructuring activities, together with the labor diagram introduced on August 19, 2004 as up-to-date on September 30, 2004 and December 14, 2004, together with the edge for better specific charges to exist incurred in reference to restructuring moves compared to the estimated charges of such actions; cautious or reduced spending via Nortel's valued clientele; elevated consolidation among Nortel's customers and the exigency of purchasers in Definite markets; fluctuations in Nortel's working outcomes and typical business, economic and market conditions and boom fees; fluctuations in Nortel's money flow, stage of staggering debt and current debt rankings; Nortel's monitoring of the capital markets for opportunities to multiply its capital structure and monetary flexibility; Nortel's capability to recruit and withhold certified personnel; using cash collateral to serve Nortel's ordinary path enterprise actions; the dependence on Nortel's subsidiaries for funding; the influence of Nortel's described profit plans and deferred tax assets on effects of operations and Nortel's cash circulate; the antagonistic resolution of classification actions, litigation within the customary path of enterprise, highbrow property disputes and similar concerns; Nortel's dependence on fresh product building and its aptitude to prophesy market require for specific items; Nortel's capacity to integrate the operations and applied sciences of bought corporations in an efficient method; the influence of swift technological and market exchange; the influence of cost and product competitors; boundaries to alien multiply and world economic conditions, notably in emerging markets and including hobby expense and currency trade fee fluctuations; the influence of clarification and consolidation in the telecommunications business; alterations in law of the information superhighway; the repercussion of the credit dangers of Nortel's customers and the repercussion of client financing and commitments; inventory market volatility generally and because of acceleration of the condense date of Nortel's forward buy contracts; contaminated tendencies associated with Nortel's supply contracts and condense manufacturing agreements, including because of using a sole supplier for a key portion of Definite optical networks solutions; the accommodate an repercussion on of Nortel's supply and outsourcing contracts that comprise beginning and installing provisions, which, if no longer met, might outcome in the payment of huge penalties or liquidated damages; and the longer term success of Nortel's strategic alliances. For additional information with recognize to unavoidable of these and different elements, espy probably the most contemporaneous Annual file on form 10-okay and Quarterly document on form 10-Q filed through Nortel with the SEC. unless otherwise required through material securities laws, Nortel disclaims any aim or responsibility to update or revise any forward-searching statements, whether on account of fresh tips, future events or otherwise.

Nortel, the Nortel brand and the Globemark are trademarks of Nortel Networks. Symon, Symon enterprise Server, Symon NetLite II, Symon group, Symon TargetVision and Symon Vista are emblems of Symon Communications, Inc.

Use of the terms "partner" and "partnership" doesn't hint a criminal partnership between Nortel and every other birthday party.




Killexams.com 920-130 Dumps and actual Questions

100% actual Questions - Exam Pass Guarantee with high Marks - Just Memorize the Answers



920-130 exam Dumps Source : Symposium Express convoke Center

Test Code : 920-130
Test appellation : Symposium Express convoke Center
Vendor appellation : Nortel
: 57 actual Questions

where must I badge in for 920-130 exam?
I commenced virtually considering 920-130 exam simply when you explored me approximately it, and now, having chosen it, I sense that I accommodate settled at the proper preference. I handed examination with exclusive opinions utilising killexams.Com Dumps of 920-130 examination and got 89% marks which is very qualified for me. In the wake of passing 920-130 exam, I accommodate numerous openings for labor now. Much liked killexams.Com Dumps for assisting me evolution my vocation. You shaked the beer!


Got no problem! 3 days preparation of 920-130 actual test questions is required.
It is not the primary time i am using killexamsfor my 920-130 exam, i accommodate attempted their materials for some vendors examinations, and havent failed as soon as. I absolutely reckon on this steering. This time, I additionally had some technical problems with my pc, so I had to handle their customer advocate to double test some thing. Theyve been top notch and accommodate helped me benign matters out, in spite of the fact that the problem become on my prevent, not their software program program.


can you disagree with that every one 920-130 questions I had accommodate been requested in actual check.
hi! im julia from spain. exigency to bypass the 920-130 exam. however. My English may exist very bad. The language is effortless and lines are quick . No worry in mugging. It helped me wrap up the guidance in 3 weeks and i surpassed wilh 88% marks. now not capable of crack the books. lengthy strains and difficult words accomplish me sleepy. needed an immaculate manual badly and finally observed one with the killexams.com mind dumps. I were given every sole query and reply . first rate, killexams! You made my day.


Dumps today's 920-130 exam are to exist had now.
I will hint you to Come birthright here to remove every sole fears related to 920-130 certification due to the fact this is a wonderful platform to tender you with confident goods for your preparations. I became involved for 920-130 examination but every sole course to killexams.Com who supplied me with tremendous products for my coaching. I become actually involved approximately my success however it changed into best 920-130 exam engine that increased my achievement self credence and now I am emotion satisfaction in this unconditional assist. Hats off to you and your incredible services for every sole college students and professionals!


Did you attempted this exceptional source of latest dumps.
Hi Team, I accommodate completed 920-130 in first attempt and thanks a lot for your useful question bank.


actual retract a view at questions of 920-130 exam are to exist had now.
in case you exigency proper 920-130 schooling on how it works and what are the assessments and every sole then dont blow it unhurried and opt for killexams.com as its miles an closing supply of assist. I additionally wanted 920-130 education and i even opted for this super check engine and were given myself the first-class education ever. It guided me with each thing of 920-130 examand provided the pleasant questions and solutions i accommodate ever visible. The retract a view at courses additionally were of very much help.


Do no longer blow some time on looking, simply glean the ones 920-130 Questions from actual test.
i accommodate advised about your gadgets to numerous partners and companions, and theyre every sole extraordinarily fulfilled. a mighty deal obliged killexams.com Questions & solutions for boosting up my career and helping me diagram nicely for my excessiveexams. a whole lot preferred over again. I exigency to whisper that i am your greatest fan! I want you to recognize that I cleared my 920-130 exam these days, deliberating the 920-130 route notes i purchased from you. I solved 86/95 questions within theexam. you are the character training company.


proper here is proper supply brand newmodern dumps, reform solutions.
I had taken the 920-130 instruction from the killexams.Com as that modified into a nice platform for the training and that had ultimately given me the fine degree of the steerage to glean the splendid scores inside the 920-130 retract a glance atchecks. I simply loved the manner I got the topics completed within the thoughtprovoking manner and through the serve of the identical; I had in the long dash had been given the detail on the line. It had made my guidance a qualified buy less knotty and with the serve of the killexams.Com I were capable of develop well within the existence.


I sense very assured with 920-130 exam bank.
that is an without a doubt cogent and dependable resource, with actual 920-130 questions and accurate answers. The checking out engine works very smooth. With extra info and suitable customer support, this is an incredibly desirable provide. No free random braindumps available on line can examine with the fine and the coolest luxuriate in I had with Killexams. I exceeded with a virtually exorbitant score, so Im telling this primarily based on my private experience.


Very tough 920-130 examination questions asked within the examination.
killexams.Com is the most nice course i accommodate ever lengthy beyond over to glean geared up and skip IT checks. I desiremore people thought approximately it. But then, there is probably greater risks someone must close it down. The constituent is, it provides for the very problem what I should apprehend for an examination. Whats more I stand for various IT assessments, 920-130 with 88% marks. My companion utilized killexams.Com for lots special certificates, every sole terrific and big. In reality stable, my individual top alternatives.


Unquestionably it is arduous assignment to pick dependable certification questions/answers assets regarding review, reputation and validity since individuals glean sham because of picking incorrectly benefit. Killexams.com ensure to serve its customers best to its assets concerning exam dumps update and validity. The vast majority of other's sham report dissension customers Come to us for the brain dumps and pass their exams joyfully and effortlessly. They never trade off on their review, reputation and character on the grounds that killexams review, killexams reputation and killexams customer conviction is imperative to us. Uniquely they deal with killexams.com review, killexams.com reputation, killexams.com sham report objection, killexams.com trust, killexams.com validity, killexams.com report and killexams.com scam. On the off haphazard that you espy any untrue report posted by their rivals with the appellation killexams sham report grievance web, killexams.com sham report, killexams.com scam, killexams.com protest or something fondness this, simply recollect there are constantly abominable individuals harming reputation of qualified administrations because of their advantages. There are a huge number of fulfilled clients that pass their exams utilizing killexams.com brain dumps, killexams PDF questions, killexams hone questions, killexams exam simulator. Visit Killexams.com, their specimen questions and test brain dumps, their exam simulator and you will realize that killexams.com is the best brain dumps site.

Back to Braindumps Menu


000-278 questions answers | 000-853 drill test | 000-541 examcollection | 000-975 brain dumps | CIA-II free pdf | COG-480 test prep | 650-312 exam prep | 000-N19 questions and answers | 000-229 pdf download | HP2-B71 actual questions | C90-06A free pdf | S90-01 drill test | OCS free pdf download | VCAP5-DCD braindumps | 050-640 test questions | HP0-J40 test prep | CAT-240 VCE | 9L0-007 mock exam | 920-195 braindumps | C2090-424 drill questions |


920-130 exam questions | 920-130 free pdf | 920-130 pdf download | 920-130 test questions | 920-130 real questions | 920-130 practice questions

Slaughter your 920-130 exam at first attempt!
killexams.com Nortel Certification study guides are setup by IT professionals. Lots of students accommodate been complaining that there are too many questions in so many drill exams and study guides, and they are just tired to afford any more. Seeing killexams.com experts labor out this comprehensive version while silent guarantee that every sole the learning is covered after deep research and analysis. Everything is to accomplish convenience for candidates on their road to certification.

killexams.com accommodate its experts operating continuously for the collection of actual exam questions of 920-130. every sole the pass4sure questions and answers of 920-130 accrued by their institution are seemed into and updated by using their 920-130 assured group. They stay related to the applicants showed up inside the 920-130 test to glean their reviews about the 920-130 test, they accumulate 920-130 exam suggestions and traps, their revel in about the tactics applied as a portion of the actual 920-130 exam, the errors they achieved in the actual exam and later on modify their material as needs be. Click http://killexams.com/pass4sure/exam-detail/920-130 killexams.com Huge Discount Coupons and Promo Codes are as underneath;
WC2017 : 60% Discount Coupon for every sole tests on website
PROF17 : 10% Discount Coupon for Orders more than $69
DEAL17 : 15% Discount Coupon for Orders greater than $99
OCTSPECIAL : 10% Special Discount Coupon for every sole Orders
When you luxuriate in their pass4sure questions and answers, you will sense positive about every one of the subject matters of exam and feel that your perception has been notably moved forward. These pass4sure questions and answers arent simply drill questions, those are actual exam questions and answers that are sufficient to pass the 920-130 exam at the first attempt.

killexams.com accommodate their experts Team to guarantee their Nortel 920-130 exam questions are dependably the most current. They are at the whole extraordinarily familiar with the exams and testing consciousness.

How killexams.com maintain Nortel 920-130 exams updated?: they accommodate their uncommon procedures to realize the maximum recent exams statistics on Nortel 920-130. Now after which they handle their accomplices who're especially at ease with the exam simulator recognition or once in a while their customers will email us the latest enter, or they were given the most current update from their dumps carriers. When they determine the Nortel 920-130 exams changed then they updates them ASAP.

On the off prep that you honestly Come up quick this 920-130 Symposium Express convoke headquarters and might pick no longer to sit tight for the updates then they will give you plenary refund. however, you should route your score reply to us with the goal that they will accommodate a exam. They will give you plenary refund quick amid their working time when they glean the Nortel 920-130 score document from you.

Nortel 920-130 Symposium Express convoke headquarters Product Demo?: they accommodate both PDF model and Testing Software. You can exam their product web page to perceive what it would appear that like.

At the point when will I glean my 920-130 cloth once I pay?: Generally, After successful payment, your username/password are sent at your e mail cope with within 5 min. It may besides retract tiny longer in case your answers postpone in freight authorization.

killexams.com Huge Discount Coupons and Promo Codes are as underneath;
WC2017 : 60% Discount Coupon for every sole tests on website
PROF17 : 10% Discount Coupon for Orders extra than $69
DEAL17 : 15% Discount Coupon for Orders extra than $ninety nine
OCTSPECIAL : 10% Special Discount Coupon for every sole Orders


920-130 Practice Test | 920-130 examcollection | 920-130 VCE | 920-130 study guide | 920-130 practice exam | 920-130 cram


Killexams C2180-529 brain dumps | Killexams ST0-47W drill test | Killexams VCP410 actual questions | Killexams ST0-130 drill Test | Killexams 000-419 study guide | Killexams 000-139 VCE | Killexams CPHQ braindumps | Killexams TT0-101 exam prep | Killexams PET bootcamp | Killexams 000-138 examcollection | Killexams 1Z0-878 mock exam | Killexams DC0-261 free pdf download | Killexams C9560-652 drill test | Killexams EW0-100 dumps | Killexams HP0-760 free pdf | Killexams 00M-225 dump | Killexams 000-M91 drill questions | Killexams ITIL-F questions and answers | Killexams CLEP exam prep | Killexams HP2-B129 brain dumps |


killexams.com huge List of Exam Study Guides

View Complete list of Killexams.com Brain dumps


Killexams P2050-006 questions and answers | Killexams 000-191 drill test | Killexams MB3-214 study guide | Killexams 500-170 questions and answers | Killexams JN0-330 braindumps | Killexams 920-325 dumps | Killexams 310-053 bootcamp | Killexams 000-007 braindumps | Killexams LOT-803 actual questions | Killexams LOT-404 free pdf | Killexams HP0-M18 drill test | Killexams ITILF2011 free pdf | Killexams LOT-986 exam prep | Killexams CPEA questions answers | Killexams 1Z0-864 examcollection | Killexams HPE6-A29 dumps questions | Killexams A6 pdf download | Killexams C4040-129 brain dumps | Killexams 9A0-383 VCE | Killexams 922-093 free pdf |


Symposium Express convoke Center

Pass 4 sure 920-130 dumps | Killexams.com 920-130 actual questions | https://www.textbookw.com/

TravelCenters of America LLC Third Quarter 2018 Conference convoke Scheduled for Monday, November 5th | killexams.com actual questions and Pass4sure dumps

WESTLAKE, Ohio--(Business Wire)--TravelCenters of America LLC (Nasdaq: TA) today announced that it plans to issue a press release containing its third quarter 2018 pecuniary results before the Nasdaq opens for trading on Monday, November 5, 2018. Later that morning, at 10:00 a.m. Eastern Time, Chief Executive Officer Andy Rebholz, President and Chief Operating Officer Barry Richards and Chief pecuniary Officer and Treasurer Bill Myers will host a conference convoke to review the third quarter 2018 results and to retract questions.

The conference convoke telephone number is (877) 329-4614. Participants calling from outside the United States and Canada should dial (412) 317-5437. No pass code is necessary to access the convoke from either number. Participants should dial in about 15 minutes prior to the scheduled start of the call. A replay of the conference convoke will exist available through Monday, November 12, 2018. To hear the replay, dial (412) 317-0088. The replay pass code is 10123843.

A live audio webcast of the conference convoke will besides exist available in a listen-only mode on the company's website, which is located at www.ta-petro.com. Participants who want to access the webcast should visit the company's website about five minutes before the call. The archived webcast will exist available for replay on the company's website after the call.

About TravelCenters of America LLC:

TA's nationwide business includes travel centers located in 43 U.S. states and in Canada and standalone restaurants in 13 states. TA's travel centers operate under the "TravelCenters of America," "TA," "TA Express," "Petro Stopping Centers" and "Petro" brand names and tender diesel and gasoline fueling, restaurants, truck repair services, travel/convenience stores and other services designed to provide attractive and efficient travel experiences to professional drivers and other motorists. TA's standalone restaurants operate principally under the "Quaker Steak & Lube" brand name.

TravelCenters of America LLCKatie Strohacker, 617-796-8251Senior Director, Investor Relations


Gilead Sciences Inc (GILD) Q3 2018 Earnings Conference convoke Transcript | killexams.com actual questions and Pass4sure dumps

Image source: The Motley Fool.

Gilead Sciences Inc  (NASDAQ: GILD)Q3 2018 Earnings Conference CallOct. 25, 2018, 4:30 p.m. ET

Ladies and gentlemen, thank you for standing by, and welcome to the Gilead Sciences Third Quarter 2018 Earnings Conference Call. My appellation is Cherie, and I will exist your conference operator today. At this time, every sole participants are in a listen-only mode. And as a reminder, this conference convoke is being recorded.

I would now fondness to whirl the convoke over to Sung Lee, Vice President of Investor Relations. please travel ahead.

Thank you, Cherie, and qualified afternoon, everyone. Just after market close today, they issued a press release with earnings results for the third quarter 2018. The press release and particular slides are available on the Investor Relations section of the Gilead website.

The speakers on today's convoke will exist Robin Washington, Executive Vice President and Chief pecuniary Officer; Laura Hamill, Executive Vice President, Worldwide Commercial Operations; John McHutchison, Chief Scientific Officer and Head of Research and Development; and John Milligan, President and Chief Executive Officer.

Before they inaugurate with their prepared comments, let me remind you that they will exist making forward-looking statements, including plans and expectations with respect to products, product candidates, pecuniary projections and the employ of capital, every sole of which involve unavoidable assumptions, risks and uncertainties that are beyond their control and could cause actual results to vary materially from these statements. A description of these risks can exist establish in their latest SEC disclosure documents and recent press releases. In addition, Gilead does not undertake any duty to update any forward-looking statements made during this call.

Non-GAAP pecuniary measures will exist used to serve you understand the company's underlying business performance. The GAAP to non-GAAP reconciliations are provided in the earnings press release, as well as on the Gilead website.

I will now whirl the convoke over to Robin.

Thank you, Sung, and qualified afternoon, everyone. They are pleased to share their pecuniary results for the third quarter of 2018. Before I glean into the pecuniary results and commercial highlights for the quarter, I'd fondness to welcome Laura Hamill, who recently joined Gilead as Executive Vice President, Worldwide Commercial Operations. They are joyful to accommodate this key position filled, and are excited to accommodate Laura on their team.

Laura is quickly becoming familiar with their business and has already provided significant commercial expertise on several strategic fronts. You'll hear from Laura in a few minutes, followed by John McHutchison with an update on their R&D efforts and then John Milligan with a few closing comments.

We had very tenacious execution in the third quarter, during which their HIV franchise achieved record quarterly sales. HCV revenues continued to exist more predictable and in-line with their expectations, and further progress was made in cell therapy, including the approval of Yescarta in Europe. Total revenues for the third quarter were $5.6 billion with non-GAAP diluted earnings per share of $1.84. This compares to total revenues of $6.5 billion and non-GAAP diluted earnings per share of $2.27 for the very term last year.

Starting with HIV, product sales for the third quarter were $3.7 billion, up 12% year-over-year and 2% sequentially. The year-over-year multiply was primarily due to the continued tenacious uptake of Genvoya and Odefsey, and the rapid adoption of Biktarvy. With 19% year-over-year revenue growth and 11% year-over-year prescription growth, their US HIV business continues to reflect tenacious underlying require for Descovy-based regimens, which now account for 74% of Gilead's total US HIV prescription volume.

Sequentially, US HIV sales were up 5%, reflecting tenacious require for Biktarvy. Payer coalesce in the third quarter was similar to the second quarter, where it was approximately equally split between private pay and government segments. In the second plenary quarter since its FDA approval in February, Biktarvy generated $375 million in sales in the US, becoming the number one prescribed regimen for both treatment-naive and switch patients. Biktarvy is on track to overtake Genvoya as the most successful launch in HIV history, as measured by the first 12 months of product sales. Approximately 85% of Biktarvy's US prescriptions came from switches. Of these switches, approximately one quarter came from regimens containing dolutegravir.

Truvada for PrEP continued to grow. They evaluate that more than 193,000 individuals were taking Truvada for PrEP as they exited the quarter. Early performance indicators for the HIV prevention and Truvada for PrEP television campaigns launched in the second quarter are encouraging. Since the launch of these campaigns, they seen dynamic date with campaign-related websites and a nearly 50% multiply in the number of weekly fresh subscribers compared to the pre-campaign averages earlier in the year.

Turning to Europe, HIV sales were down 11% year-over-year, primarily due to the availability of generics in several markets. The decline was partially offset by the continued uptake of their Descovy-based regimens, which now comprise approximately 70% of their HIV product revenues in Europe. As anticipated, they saw a sequential decline in sales in the third quarter, primarily due to the additional repercussion of generics in unavoidable countries and the seasonal repercussion of holiday schedules in various countries. To date, in some countries, the repercussion from generics has not been as significant as expected.

Since receiving marketing authorization from European Commission in June, Biktarvy has launched in Germany and some of the smaller countries in the EU. In Germany, they are seeing mighty early uptake where Biktarvy is tracking at least as well as Genvoya for the very term after approval. Also, Biktarvy is already among the top five most prescribed regimen for both treatment-naive and switch patients, with about a third of the switches coming from dolutegravir-containing regimens. Genvoya remained the number one prescribed regimen for treatment-naive and switch patients in the EU-5 collectively for the sixth consecutive quarter.

Turning to HIV (ph), product sales for the third quarter were $902 million, down 59% year-over-year and down 10% sequentially. To date, their performance in the HCV market continued to align with their expectations of gradual sequential declines with fewer patients seeking treatment. In September, they announced plans to launch authorized generic versions of Epclusa and Harvoni in the United States in January 2019 through a newly created subsidiary, Asegua Therapeutics LLC.

The list prices of the authorized generics will exist comparable to the current net prices of the branded versions. They believe these authorized generics could reduce out of pocket expenses for patients, multiply pricing transparency, and open up access to their HCV medicines for patients covered by Medicaid. This solution allows us to quickly interject a lower priced alternative to their HCV medications without significant disruption to the healthcare system or their business.

Turning to their cell therapy franchise. Sales of Yescarta were $75 million for the third quarter, up 10% sequentially. They are pleased with the progress we've made with Yescarta since its approval by the US FDA one year ago. They now accommodate 64 centers certified to provide treatment for Yescarta. As they continue to espy patient inflows at certified centers, they accommodate besides observed variability in volume as some centers enthusiastically embraced this novel therapy and others adopt treatment more slowly.

We've turned their focus to working with centers to enhance patient flows. They are besides educating community oncologists about cell therapy and how they can connect their patients to cancer centers for arrogate treatment. They expect to espy continued require as their certified centers gain broader sustain with Yescarta and community oncologists become increasingly sensible of this life-saving therapy.

Recently, CMS approved an NTAP, fresh Technology Add-on Payment, to assist the reimbursement of CAR T therapy within the hospital setting while they await the creation of a CAR T specific DRG through CMS. We're very encouraged with the hurry in which CMS has recognized the value of Yescarta for cancer patients, who accommodate dash out of treatment options in relapsed refractory DLBCL. They view forward to working with CMS to create a dedicated DRG code reflective of the value Yescarta brings to patients.

As I previously mentioned, Yescarta was approved in the EU toward the halt of August. They are working diligently across Europe to certify approximately 20 centers by the halt of 2018. They are pleased with the progress and commercial performance seen to date with Yescarta, which is consistent with their expectations. Going forward, they anticipate a constant and measured launch as reimbursement, referrals and headquarters logistics help to accommodate more patients.

Turning to their cardiovascular products, Letairis and Ranexa generated sales of $241 million and $178 million respectively in the third quarter. While the US patent for ambrisentan, the dynamic agent in Letairis expired in July of this year, they accommodate not seen any repercussion to their sales as a result of the loss of exclusivity, because the sole shared REMS program necessary to allow generic ambrisentan to launch has not yet been FDA approved. There is no specific PDUFA date associated with this approval and the timeline for FDA action is unknown. As they view ahead, they anticipate Letairis sales to continue for the residue of this year. However, sales beyond this timeframe are uncertain.

Now turning to expenses, non-GAAP R&D expenses were $844 million for the third quarter, up 13% compared to the very term last year. Non-GAAP SG&A expenses were $852 million for the third quarter, up 6% compared to the very term last year. The increases in both non-GAAP R&D expenses and SG&A expenses were primarily due to higher costs to advocate the growth of their business following the acquisition of Kite.

Our non-GAAP efficient tax rate in the third quarter was 19.9% compared to 25.7% in the very term last year, primarily due to reduction of the US corporate tax rate as a result of Tax Reform. On a sequential basis, their non-GAAP efficient tax rate was higher compared to the second quarter rate of 13.4% due to a propitious settlement of a tax examination in the second quarter.

Moving to their equilibrium sheet. As of September 30, 2018, they had $30.8 billion of cash and investments. During the third quarter, they generated $2.2 billion in operating cash flow, repaid $1.8 billion senior notes upon maturity, paid cash dividends of $742 million, and repurchased approximately 6 million shares of stock for $449 million. The year is progressing consistent with their expectations, with the exception of the durability of Letairis revenues and the lower repercussion of HIV generics. The combined profit from these two exceptions is approximately $400 million. Therefore, they are raising their full-year net product sales guidance.

Net product sales are expected to exist in the orbit of $20.8 billion to $21.3 billion. Their guidance is subject to a number of uncertainties which are outlined in slip 35 of their earnings convoke presentation. For the full-year, their non-GAAP efficient tax rate is expected to exist in the orbit of 18% to 20%. every sole other components of their guidance remain unchanged.

I will now whirl the convoke over to Laura.

Laura Hamill -- Executive Vice President, Worldwide Commercial Operations

Thank you, Robin, and qualified afternoon. I'm thrilled to exist portion of the Gilead team and treasure how welcoming everyone has been during my first six weeks as I'm getting to know the captious success factors for their current and future therapies. I've had the opportunity to learn more about Gilead's portfolio by participating in several therapeutic advisory board meetings, scientific conferences, visiting some of their cancer institutions that are providing treatments with Yescarta, and engaging with many passionate Gilead employees. The commercial and territory teams accommodate a deep commitment to advocate healthcare providers as they meet the needs of patients around the world. It's a privilege to exist joining Gilead at this time with the introduction of Yescarta as well as Biktarvy, which is on track for an outstanding launch. They are continuing to shift treatment paradigms.

I besides want to own the innovative approach the team has taken in the United States to multiply access to their hepatitis C treatments. Next year their subsidiary Asegua will launch authorized generic versions of Harvoni and Epclusa, a medication they believe has a unique clinical profile as a pan-genotypic and pan-fibrotic single-tablet regimen. As they prepare for their next set of launches, they will bring their deep expertise in building fresh markets, as well as capabilities to compete in existing markets with many therapeutic options.

The teams around the world are motivated by Gilead's mission to bring innovative medicine to more than 13 million patients with life-threatening illnesses. I view forward to sharing their commercial progress with you during their next quarterly update. I will now whirl the convoke over to John McHutchison.

John McHutchison -- Chief Scientific Officer and Head of Research and Development

Thank you, Laura. Welcome and thank you, everybody for joining us today. I'd fondness to start by talking about the progress they are making across their later-stage pipeline. As they enter the final quarter of the year and view ahead to 2019, they anticipate readouts from five angle 3 studies over the next nine months. The American College of Rheumatology Meeting finished yesterday in Chicago. So I'll inaugurate with some commentary about their labor in the belt of inflammation, starting with filgotinib, which as you know, is the selective JAK1 inhibitor.

Last month they announced positive results from FINCH 2, the first of three angle 3 studies to readout in patients with rheumatoid arthritis. FINCH 2 compares filgotinib to placebo, each added to conventional disease-modifying anti-rheumatic drugs, or DMARDs in 423 patients who accommodate previously not had an adequate response to biologic therapy. Filgotinib was generally well tolerated and met the study's primary endpoint in terms of the harmony of patients achieving an ACR20 at week 12.

In addition, key secondary endpoints, including ACR50 and ACR70 responses and the rates of low disease activity and remission were every sole higher with filgotinib compared to placebo. Importantly for these endpoints, they besides renowned a dose dependency as efficacy rates were numerically higher with the 200 milligram once daily dose of filgotinib, compared to the 100 milligram daily dose. The initial readout of the first angle 3 data adds to their excitement about the potential of filgotinib, obviously.

We expect results from two other angle 3 studies of filgotinib, FINCH 1 and FINCH 3, to exist available in the first quarter of next year, and it's supported by the data to form the basis of their filings for regulatory approvals globally. As a reminder, FINCH 1 is a 52 week randomized study comparing both doses of filgotInib, plus methotrexate to adalimumab plus methotrexate and to methotrexate alone in patients who accommodate previously had an inadequate response to methotrexate. FINCH 3 is a 52 week randomized study comparing filgotinib alone to methotrexate alone and to the combination of filgotinib plus methotrexate in methotrexate-naive patients.

Now their aptitude to file the NDA for filgotinib is conditional on data from the MANTA study. As you may recall, MANTA is a safety study in men with ulcerative colitis that was requested by the FDA and is designed to address non-clinical findings observed in preclinical animal studies. Because their angle 3 FINCH trials accommodate enrolled more rapidly than anticipated, enrollment in MANTA will likely exist the rate limiting factor to filing an NDA in the United States. While they accommodate been making every pains to expedite enrollment, the plenary repercussion of the efforts and their repercussion on the overall timeline are uncertain at this time.

Results from the EQUATOR study, a angle 2 trial of filgotinib in 131 adults with dynamic psoriatic arthritis were presented this week at ACR in a plenary session and concurrently published in The Lancet. The study besides achieved its primary endpoint of improvement in the signs and symptoms of psoriatic arthritis at week 16. The study demonstrated an impressive ACR20 response of 80% to filgotinib 200 milligrams daily, versus 33% for placebo. The ACR50 and ACR70 responses were besides significantly higher for filgotinib compared to placebo. Based upon the force of these data, they are excited to exist initiating plans for their angle 3 program and are enthusiastic about what this may stand for for people animated with psoriatic arthritis and whose disease is not responded to prior treatments.

Last month they announced that filgotinib met its primary efficacy endpoint in the angle 2 TORTUGA study in adults with moderately to severely dynamic ankylosing spondylitis. Patients treated with filgotinib achieved significantly greater improvement in the ankylosing spondylitis disease activity score at week 12 compared to placebo. These results which were besides published in The Lancet this week, compare favorably to those seen with other known DMARDs commonly known to handle ankylosing spondylitis patients. We'll determine the next steps for the program in the coming months.

Finally in the inflammation therapeutic area, I'm pleased to share that a angle 2 study evaluating three investigational therapies, filgotinib; GS-9876, a Syk inhibitor; and tirabrutinib, a BTK inhibitor in patients with dynamic Sjogren syndrome has fully enrolled 140 patients.

Now turning to HIV, they presented 96-week data at IDWeek in San Francisco earlier this month from an ongoing angle 3 study evaluating the safety and efficacy of Biktarvy for the treatment of HIV infection in treatment-naive adults. The data at two years substantiate the efficacy and safety profile of Biktarvy and showed that Biktarvy continued to exist well tolerated with no cases of treatment-emergent resistance.

Moving on to liver diseases. The Liver Meeting will exist held in San Francisco early next month, where they will present data from more than 50 abstracts across their programs in NASH, primary sclerosing cholangitis, hepatitis B and hepatitis C. In NASH, they are advancing multiple investigational compounds for the treatment of advanced fibrosis, that is patients with Stage 3 and Stage 4 fibrosis. Individuals with these advanced stages of fibrosis are at a significantly higher risk of liver-related mortality.

The data being presented further characterize the potential role of three compounds they accommodate in development, their FXR agonist, GS-9674, their ASK1 inhibitor, selonsertib and their ACC inhibitor, GS-0976. They will besides present baseline data from STELLAR 3 and STELLAR 4, their two ongoing angle 3 trials evaluating selonsertib as monotherapy that record the potential role and sequence of non-invasive tests and their aptitude to diagnose advanced fibrosis. Currently, liver biopsy, which is the benchmark method to diagnose advanced fibrosis, poses challenges to timely and efficient diagnosis and treatment of patients with this disease.

Before they slump on from NASH, I'd fondness to remind you that they anticipate data readouts from STELLAR 3 and STELLAR 4 in the first half of 2019. They are besides pleased to share that the angle 2b ATLAS study of various combination two-drug regimen in patients with NASH and advanced fibrosis has now closed screening. They are presenting data from a angle 2 trial evaluating their FXR agonist in primary sclerosing cholangitis. This is a rare earnest disease that causes progressive inflammation and scarring of the bile ducts which can lead to cirrhosis and its complications, including liver failure. There are currently no efficient treatment options available for these patients.

And finally at The Liver Meeting, they will besides share data from Gilead's ongoing programs directed at achieving functional heal of inveterate hepatitis B infected patients. GS-9688, an investigational oral selective toll-like receptor 8 agonist is the subject of several studies to exist presented, including the first in human and angle 1b results evaluating the drug in patients with inveterate hepatitis B.

Turning to cell therapy, they continue to accomplish mighty scientific progress besides during the quarter. In August, they announced that European Commission granted Marketing Authorization for Yescarta as a treatment for adult patients with relapsed or refractory diffuse big B-cell lymphoma and primary mediastinal big B-cell lymphoma, after two or more lines of systemic therapy. They are making progress in reaching patients with other forms of B-cell malignancies also, with Yescarta and KTE-X19 (ph). Registrational angle 2 trials are ongoing with Yescarta in relapsed and refractory indolent NHL or non-Hodgkin's lymphoma and with KTE-X19 (ph) in relapsed and refractory mantle cell lymphoma and adult ALL.

We expect to advertise additional data and trial updates from their cell therapy program at the American Society of Hematology Annual Meeting, ASH, which begins December 1 in San Diego. They will share more information with you next month when those meeting abstracts are published.

Separately in oncology, they discontinued the evolution of andecaliximab, an investigational anti-MMP9 antibody in gastric cancer, after a angle 3 study showed a exigency of overall survival profit to primary endpoint. These data are consistent with the results we're seeing with andecaliximab in other therapeutic programs.

We continued to pursue additional technologies and approaches that will allow us to remain the leader in cell therapy. Earlier this month, they announced another research collaboration and license agreement with HiFiBiO Therapeutics to develop technologies supporting the discovery of neoantigen-reactive T-cell receptors for the potential treatment of various cancers, particularly solid tumors.

Through this collaboration, they intend to adjust HiFiBiO's proprietary single-cell technology platform to create a high throughput approach that will potentially allow for in-depth screening of TCR repertoires from patient samples to identify both shared antigen and neoantigen TCRs for employ in adoptive T-cell therapy. Neoantigens arise from tumor specific mutations that are unique to each patient's cancer, offering the potential for more targeted anti-tumor activity. This belt of research has the potential to transform the course they might exist able to handle many solid tumors.

I would fondness to besides note that these kinds of scientific collaborations are not limited to cell therapy. In September, they entered into a strategic collaboration with Precision BioSciences to develop therapies targeting the in vivo elimination of HBV or hepatitis B virus with Precision's proprietary genome editing platform, ARCUS. They are committed to developing therapies to achieve a functional heal for patients with inveterate hepatitis B virus. They are excited about the potential of genome editing and Precision's ARCUS technology, which has already demonstrated promising in vitro activity.

We accommodate achieved a mighty deal across their R&D organization this quarter, and I'm confident they will continue to accomplish significant progress throughout the relaxation of the year. I'm excited about the force and diversity of their pipeline, as described today, the breakthrough labor they are doing in cell therapy and the cutting-edge research they are doing to advance curative therapies, both for hepatitis B and HIV infected patients. I want to retract the opportunity to thank their R&D organization and every sole of their employees for their incredible focus, arduous labor and execution.

So, thank you all. And now, I'd fondness to whirl the convoke over to John Milligan.

John Milligan -- President and Chief Executive Officer

Thank you, John. qualified afternoon, everyone. As they approach the halt of the year and head into 2019, they accommodate many reasons to feel confident about the force of their business and the future of their company. Their long-term leadership in HIV continues. We're having a terrific launch of Biktarvy, which is exceeding their high expectations and is on track to become the most successful ever in HIV through the first year of sales. They besides accommodate compelling evidence correlating the employ of Truvada for PrEP with declines in fresh infections in the United States, further demonstrating its consequence as an efficient public health intervention in the ongoing efforts to meaningfully abate fresh infections.

While mighty progress has been made in both treatment and prevention over the last two decades, they believe there is silent plenty of elbowroom for innovation in HIV. They are pursuing research that could serve patients who accommodate dash out of options as a result of viral resistance or who may exigency less frequent dosing than afforded by a daily pill. And finally, they hope that their research may one day serve lead to a cure, completely removing the virus from patients once and for every sole as they did for patients in HCV.

In HCV, they continue to innovate to expand access and advocate efforts toward elimination of the virus from the human population. In January, just over five years after the launch of Sovaldi, their newly formed subsidiary, Asegua, they will launch authorized generic versions of Epclusa and Harvoni in the United States. They believe this will serve reduce out of pocket expenses for many patients, multiply cost transparency and open up access to their HCV medicines for patients covered by Medicaid without disruption to the broader healthcare environment.

One year after the acquisition of Kite, Gilead is the leader in cell therapy and Yescarta access for people with the relapsed refractory DLBCL is now established in over 60 centers in the United States. Yescarta has shown an unprecedented duration of response in clinical studies, and they accommodate now treated nearly 700 patients across clinical trials and commercial use. The high percentage of patients showing a durable response following the sole cellular fusion gives us a glimpse into the potential of cellular therapy to radically change the cancer treatment paradigm in the future, perhaps across many different tumor types. Over the last year, they accommodate established six technology product-based partnerships that will allow us to build on their leadership position in cell therapy and transform the treatment of cancer.

We accommodate a maturing pipeline and are now beginning to espy the first of many angle 3 readouts of filgotinib in inflammation. They are pleased that the efficacy and safety of filgotinib looks to exist consistent with the datasets from the long-term angle 2 studies and believe filgotinib shows mighty swear to serve patients in a number of different indications.

Finally, Gilead has dedicated huge resources to understanding the biology and pathology of NASH. These efforts are paying off with three compounds in the clinic, including an extensive array of angle 2 combination studies. Next year, we'll espy the first angle 3 readouts of selonsertib as the STELLAR 3 and STELLAR 4 clinical studies are completed and unblinded. They view forward to seeing the data, and their teams are arduous at labor preparing for the launch of selonsertib into this brand fresh disease area.

The labor of Gilead goes on, even as I prepare to depart at the halt of the year. To everyone who has supported us in their mission over the years, thank you. I accommodate every aplomb in my team's aptitude to continue the labor of bringing forward therapeutics that dramatically help lives. To Gilead's more than 11,000 employees, I besides want to thank you. It's been a privilege to exist a leader for the last three years and to labor with you for the last 29. It's been deeply gratifying to exist portion of a company that has brought life-saving treatments to 10 million people around the globe. I view forward to watching the continued evolution of Gilead and the extraordinary things I know you will accomplish.

So, let's open it up for questions. Operator?

Questions and Answers:

Operator

Thank you. Ladies and gentlemen, today's question-and-answer session will exist conducted electronically. (Operator Instructions) Their first question comes from Geoff Meacham with Barclays.

Geoff Meacham -- Barclays -- Analyst

Good afternoon, everyone. Thanks for the question. John, really they will miss your leadership and I want to add congrats besides to Laura on the fresh role. Just had a few on HIV. If you guys could give any more perspective on switches to Biktarvy, beyond dolutegravir. Are you seeing switches from generic regimens as well? And then on PrEP, I know you don't accommodate data yet, but what's the initial thought on positioning for Descovy over Truvada? And how achieve you mediate that plays out following the Truvada LOE? Thank you.

Robin Washington -- Executive Vice President and Chief pecuniary Officer

So, in terms of switches, Geoff, as I mentioned, they are seeing that the majority of the Biktarvy prescriptions are coming from switches, about 85% to exist exact. And approximately a quarter of those are coming from dolutegravir containing regimens. There is besides about 25% coming from Genvoya as well, so (inaudible) balance. And then the latter half of your question, Geoff, can you reiterate it?

Geoff Meacham -- Barclays -- Analyst

Descovy for PrEP.

Robin Washington -- Executive Vice President and Chief pecuniary Officer

Oh, Descovy for PrEP. John.

John McHutchison -- Chief Scientific Officer and Head of Research and Development

Yes. John here. Look, the question of Descovy versus Truvada for PrEP, people who are healthy, which is the people who are taking PrEP are, deserve and want the easiest and safest and best tolerated medication. So that is Descovy. So I mediate that's a pretty straightforward reply to that question.

Operator

Thank you. Their next question comes from Brian Abrahams with RBC Capital Markets.

Brian Abrahams -- RBC Capital Markets -- Analyst

Hey, guys. Thanks very much for taking my question and congrats on the quarter. On filgotinib, with the angle 3 starting to rollout, I was wondering if you could provide your latest views on what you espy as the key differentiating features or indications? And maybe walk us through your latest plans in how you're thinking about building out a commercial infrastructure in inflammation, particularly with some of the fresh leadership now in place? Thanks.

John McHutchison -- Chief Scientific Officer and Head of Research and Development

So I'll start first. So, after attending ACR this week and being at the meeting, it's clear that the efficacy that they are generating in multiple inflammatory diseases with filgotinib is as qualified or if not better than any other drug in the class, and equivalent to the biologics. And that holds actual for FINCH 2 where they just saw the most difficult patients to treat, the biologic non-responders, inadequate responder patients where their ACR20 rates in people who had received three or more biologics previously was over 70%, just over 70%. So, I mediate efficacy wise, they are as qualified if not better than anything else out there in the class.

Safety wise, they continue to espy the differentiation based upon the lab parameters -- anemia, the exigency of anemia, the exigency of consequence on platelets and when they view at other clinical events such as thromboembolic events and other events, they are not seeing anything difference. They accommodate to espy that safety profit and edge hold up in the subsequent angle 3 clinical programs. The very as the other diseases, they are seeing those benefits as well. So, I'll hand it over to the other folks about the commercial build out, et cetera.

Laura Hamill -- Executive Vice President, Worldwide Commercial Operations

So, hi. This is Laura. I would whisper on the commercial structure, they will build a commercial territory team that is competitive across every sole indications. And as you know, they are sensible of the investment that's necessary to compete in this market and they will exist reaching consumers in innovative ways to accomplish sure that they are sensible of the profile that we'll exist able to bring to the market to serve them.

Operator

Thank you. Their next question comes from Michael Yee with Jefferies.

Michael Yee -- Jefferies -- Analyst

Thanks. treasure the question. And, John, I'm sure they every sole heard the emotion in the voice, so they treasure every sole the labor you've done and for every sole the years. I guess my question is, it feels fondness the Street has two uncertainties; one is a bit on hep C and one is, I guess, to an extent, an update on the fresh leadership that will give people aplomb going forward. Perhaps you can give a observation as to your aplomb around the US hep C market stabilizing and whether there's any changes and how that authorized generic helps that, if at all? And then if you can accomplish a observation on where they stand on the leadership change? I mediate that would serve people as well. Thanks.

John Milligan -- President and Chief Executive Officer

Yeah. Hi, Michael. So let's just -- talking about the US hep C market, what they accommodate seen through the course of the year is a fairly stable pricing environment but, of course, declining patient numbers, particularly in the commercial markets and to some extent the Medicare markets. So, they mediate the authorized generic will actually boost us for the future because number one, it provides more transparency, which is qualified for everybody. It will retract away some of the twinge of the co-pays that are provided, especially into the Medicare population. But most importantly, it'll open up access for us into the Medicaid population, which is the largest growing segment of patients for the future. So they mediate that every sole this will enhance their aptitude to compete for the future and really serve stabilize this market going into 2019 and beyond. So all-in-all, a very positive thing for us.

With admiration to the CEO search, I really can't whisper anything specific, other than to whisper there are many candidates who are very interested. The process is affecting along quickly, and they certainly hope to accommodate somebody announced before the halt of the year.

Operator

Thank you. Their next question comes from Matthew Harrison with Morgan Stanley.

Matthew Harrison -- Morgan Stanley -- Analyst

Great. qualified afternoon. Thanks for taking the question. I had one related to some of the Kite programs. I noticed in the slides you indicated that you'd exist making a decision on your BCMA CAR, whether to slump into a registrational study in the fourth quarter. I'm just wondering what data you're waiting for to accomplish that decision and how you're going to communicate that decision? Thanks.

John McHutchison -- Chief Scientific Officer and Head of Research and Development

Sure. Hi, Michael.

John Milligan -- President and Chief Executive Officer

Matt, this is Matt.

John McHutchison -- Chief Scientific Officer and Head of Research and Development

Matt, sorry. Look, yes, it's unchanged. They are waiting for data from the angle 1b trial, which is looking at escalating dose cohorts, the safety and efficacy in myeloma patients of KITE-585. And then we'll advertise the start of a angle 2 trial if the data supports that. So, no change to what we've said previously and we're in the process of that birthright now.

Operator

Thank you. Their next question comes from Geoffrey Porges with Leerink.

Geoffrey Porges -- Leerink -- Analyst

Thank you very much. And, John, I just want to congratulate you on every sole the accomplishments over those 29 years. I'm sure if you accommodate any free time, John McHutchison might lend you his AO for a bit of travel. I just wanted to put a question to John McHutchison a tiny bit about a brace of pipeline contingencies. First, you mentioned the MANTA study. And obviously, you'll accommodate the three FINCH studies by the -- in the first half of the year. Is it practicable that, that filing could exist delayed until 2020? Or is there any course you could start filing with the clinical data and then append the MANTA data to the filing?

And then secondly, will you accommodate a haphazard to view at the interim data from the combination NASH study and then potentially contemplate pivotal trials to some combination earlier than the 48-week data? Thanks.

John Milligan -- President and Chief Executive Officer

Yeah.

John McHutchison -- Chief Scientific Officer and Head of Research and Development

Thank you, Geoff. Starting with MANTA, mighty question. They accommodate spent an inordinate amount of pains trying to enhance the enrollment in the MANTA study. It's too early to gauge the effectiveness of those modifications to inclusion criteria, et cetera. I mediate we'll provide an update in the future when they can accommodate more clarity about the timeline.

I will whisper they are having discussions internally and with regulators about different options, as one of which you outlined as well. And as you know, in various parts of the world you can file and you can file updates at various different times of the review process. So each region and each belt is different. So we're having every sole of these discussions and spending a lot of my pains and a lot of the team's pains on that as well.

In terms of the ATLAS, your second question, in terms of the ATLAS angle 2b 350 patient NASH combination study. Yes, they will retract a view at week 24. And week 24 view we're allowed to achieve an statistical analysis plan. It's not biopsy-driven, it's driven by MRA FibroScan, lab tests, MRI-PDFF. So they will exist able to accommodate a look. And if there's clear separation without biopsy, they can determine to slump early to angle 3 if we're convinced that's the birthright thing to do.

Operator

Thank you. Their next question comes from Robyn Karnauskas with Citi.

Greg Harrison -- Citi -- Analyst

Hi. This is Greg Harrison on for Robyn. Thank you for taking the question. So in hep B, given the Arrowhead data we've seen recently, achieve you mediate that you exigency an S antigen component in your combos? Or are you satisfied with what you accommodate internally?

John McHutchison -- Chief Scientific Officer and Head of Research and Development

I don't mediate we're ever satisfied with what they accommodate internally. And they accommodate a number of internal programs that are looking at interfering in S in various different ways, either by direct mechanisms or through induction of HBV-specific immunity. And they are besides always looking for what they mediate is additionally valuable to what they are doing internally, externally as well. They are watching the siRNA territory closely besides and sensible of what Arrowhead's done. They view forward to seeing the data presented in plenary at AASLD.

Operator

Thank you. Their next question comes from Umer Raffat with Evercore.

Umer Raffat -- Evercore -- Analyst

Hi, guys. Thanks for taking my question. And John, wanted to extend their congratulations on every sole of your's and Gilead's success over the years. My question was perhaps two-fold. One, going forward for the fresh CEO, is there specific expectations that the board has set? May that exist on specific M&A targets, dollar size, number of transactions? Just wanted to glean a flavor for the direction for the company and board's expectations.

And then secondly on CAR T, they heard your commentary on the variability in adoption. And my question is, Street has a 50% growth over the next four quarters for Yescarta franchise. And given how notable a launch it is, my question is, achieve you remain confident in that type of growth trajectory?

John Milligan -- President and Chief Executive Officer

So first let me start with the specific criteria for a fresh CEO. That's not typically how things are done. There are conversations and looking at different strategies that a fresh CEO could bring to Gilead. But, no, there are no specific targets or directions that were given by the board.

So secondly, and question about CAR T is a qualified one. So if you mediate about CAR T and you mediate about the shift in paradigm that has to occur in a treatment headquarters to adopt it, it requires lots of collaboration across multiple departments. It requires novel ways of thinking about billing and treating patients. And it takes time for these centers to Come up to speed. The centers that were early adopters of CAR T and are silent the biggest users of Yescarta, accommodate a lot of sustain and accommodate benign of worked out the treatment, and frankly, business paradigm of cellular therapy. And that's where we're seeing the majority of their success today.

The middle adopters and now the late adopters are the groups that are really trying to motif out how to accomplish this labor within their institution and how to accomplish this business model labor for their hospital in particular and that can retract some time. So what they would expect is that, as these centers start to treat, as they labor out how to build the commercial plans, as they motif out how to glean reimbursement through -- for Medicare patients, this will grow over time. And, of course, we'll espy some centers that accommodate greater adoption and some that accommodate less.

So, I achieve mediate that with the data that are emerging on CAR T with the growing body of evidence that a high percentage of patients can accommodate very durable responses, this is something that will grow to become of consequence in every sole 60 centers that we're in. But it is going to retract some time to glean the growth rate that they need. I won't observation to any specifics. But I'm very confident that as they glean better at this, as the medical drill gets better, as they glean better at managing some of the side effects around this, and then importantly in the future, as they glean a DRG code, this will grow into a very notable business for Gilead. And it will exist very, very notable for patients who accommodate dash out of options.

Operator

Thank you. Their next question comes from Alethia immature with Cantor Fitzgerald.

Alethia immature -- Cantor Fitzgerald -- Analyst

Hey, guys. Thanks for taking my question. Congrats on Biktarvy. And John, you certainly will exist missed and they truly enjoyed seeing him serving the leadership over such a long tenure. I guess I accommodate a question on HIV and generics in Europe. You said obviously you've seen some repercussion and there actually accommodate been some company -- countries where you haven't thought -- you thought you would espy repercussion and didn't. So, can you talk a tiny bit more about those unavoidable dynamics there? Thanks.

Robin Washington -- Executive Vice President and Chief pecuniary Officer

Sure, Alethia. Congrats on your fresh role as well. Yeah, they continue to espy adoption of generics across Europe. I mediate what we're seeing is differentiation across the different countries relative to timing and the uptake of generics. They talked about the uptake of Descovy, that continues to travel really well and they mediate that's thwarting some of that uptake. Particularly in Italy and UK, we're just not seeing the uptake of generics as quickly as they thought they would retract hold. And that's something that they factored into their guidance to the tune of $100 million. I mediate even in 2019, we'll continue to espy uptakes of generics, but with the launch of Biktarvy, et cetera, they mediate we'll exist well competitively positioned and mediate every sole the benefits of Descovy will serve us continue to grow share in their ex-US markets.

Operator

Thank you. Their next question comes from Phil Nadeau with Cowen.

Phil Nadeau -- Cowen -- Analyst

Good afternoon. John, let me add my congratulations on every sole that you've accomplished and best of luck on your next act. My question is on the guidance. It looks fondness that even at the top halt of the guidance, you're projecting a sequentially down quarter in Q4. inquisitive to glean a tiny bit more information on what elements achieve you mediate are going to accommodate a quarter-over-quarter decline? Is that HCV? Is that EU HIV? Any information you could give us would exist appreciated. Thanks.

Robin Washington -- Executive Vice President and Chief pecuniary Officer

Sure, Phil. I won't travel -- again, they benign of gave a foundation of their guidance. First, let me just whisper we're really very satisfied with how the year has gone and the aptitude to raise guidance at this point. Everything that we've talked about from HIV being a growth franchise to HCV stabilizing, Yescarta continuing to accommodate a nice unhurried and constant build. I mean, I mediate overall, every sole of their franchises are performing very well. There's a brace of dynamics. You mentioned a few. One HCV, as they said, while stabilizing they achieve continue to espy declines in patient starts. That's the primary driver.

Recall they talked last quarter about a cost freeze for the next six months, which if you mediate about a typical Q4, they sometimes espy inventory build in Q4 in advance of that cost increase. And I'm not aphorism they won't accommodate any inventory build, some of that is just portion of supply chain, but they achieve anticipate that there may exist a tiny less. And as I mentioned, the other driver of their raise in guidance was Letairis and the LOE, which is here. They haven't seen any impacts. That could happen, right. So they are providing a orbit of guidance, but we're very confident with their aptitude to meet the guidance and hope to overachieve it.

Operator

Thank you. Their next question comes from Cory Kasimov with JPMorgan.

Cory Kasimov -- JPMorgan -- Analyst

Hey. qualified afternoon, guys. Thanks for taking my question. I guess first to John, congrats again on a really mighty run. So I guess my question is on Biktarvy on the heels of another really impressive quarter for the product. I'm just inquisitive if there was any meaningful contribution from inventory build or any other type of one-time item? Or is this really every sole just demand-driven? Thanks.

Robin Washington -- Executive Vice President and Chief pecuniary Officer

Hi, Cory. mighty question. Now their sequential growth was every sole require driven. They didn't espy really any change in inventory and as you're probably recalling last quarter, I talked about the fact that they were at a 50-50 payer coalesce between commercial and government and there was the haphazard that that would accommodate shifted back to what we've traditionally seen, 45% commercial, 55% government. But they didn't espy that. And these payer coalesce percentages achieve fluctuate quarter-to-quarter really depending on the buying patterns from government payers, such as ADAP. So, overall, a tenacious demand-driven quarter for Biktarvy, again this -- and HIV overall, no repercussion from inventory or payer mix.

Operator

Thank you. Their next question comes from Terence Flynn with Goldman Sachs.

Terence Flynn -- Goldman Sachs -- Analyst

Hi. Thanks for taking the question. Maybe just a brace of follow-ups on Biktarvy and the TAF portfolio. First, can you just observation on European pricing dynamics for Biktarvy, now that you're a tiny bit further in and maybe serve us mediate about that heading into 2019? And then can you guys disclose total TAF volume in Europe birthright now? I know you give us that for the US, but just wondering where it stands in Europe? Thank you.

Robin Washington -- Executive Vice President and Chief pecuniary Officer

Yeah, So it's arduous to talk about volume because of generics. They achieve talk about TAF or Descovy based as a percentage of revenue, and it's about 70% of revenues in US. Pricing really hasn't been a barrier, withhold in mind, they priced -- their Descovy regimens are pretty much priced similar to Stribild, et cetera (inaudible) Biktarvy. So it's really been qualified overall uptake. I mediate we'll always espy competitiveness in European pricing, but that's something that we're used to. So, it really fundamentally has been just the crave for more and more patients who want to slump to Descovy-based regimens that has been driving their performance offset by the adoption of generic.

Operator

Thank you. Their next question comes from Ying Huang with Bank of America Merrill Lynch.

Ying Huang -- Bank of America Merrill Lynch -- Analyst

Hi. Thanks for taking my questions, and congrats to John as well. So, first one on Yescarta, I think, Robin, you mentioned that now you achieve accommodate this fresh technology add-on payment. I was wondering how much that helps the adoption for Yescarta under that? And how much is this pecuniary loss is actually stopping the centers from adopting Yescarta?

And then secondly, they noticed that you accommodate exclusive status with Express Scripts for 2019 and Mavyret from AbbVie was excluded. Does that stand for there is additional pricing concessional rebate provided by Gilead? Thank you.

Robin Washington -- Executive Vice President and Chief pecuniary Officer

So, let me start with the prior question. Yeah, I mediate as always is their case, they are always working and negotiating with payers. I won't -- can't talk specifically to the details of a contract, but they are tickled that they accommodate reached the formulary ranking with Express Scripts, and it's something that we've talked every sole about that, they continue to exist out there competing in this marketplace. There's besides Mavyret, and they continue to achieve well.

I mediate to your other question relative to Yescarta. Yeah, the NTAP, as I said, it's a start. As they understand it, it's about 50% of reimbursement. To sit and uncover you what every hospital makes or doesn't make, that's very arduous for me to observation on. That's very conditional on their relationship with the payers, et cetera. So, I can't give you more details on that. I achieve mediate the NTAP is a start, and they are working very, very diligently and arduous to continue to demonstrate the value of this treatment, and hopefully eventually espy DRG specifics for CAR T therapy.

Operator

Thank you. And their final question comes from Steven Seedhouse with Raymond James.

Steven Seedhouse -- Raymond James -- Analyst

Hi. Thank you for taking the question. Just on NASH, understanding the hope is obviously that both STELLAR 3 and STELLAR 4 succeed. I'm inquisitive if there is a viable filing strategy or path forward for either monotherapy or combination therapies for selonsertib in basically refined fibrosis subset of NASH patients if one of those two angle 3 trial hits the primary endpoint or accommodate you designed the clinical program such that both angle 3 trials exigency to labor to slump selonsertib forward? Thank you.

John McHutchison -- Chief Scientific Officer and Head of Research and Development

So, it's a qualified question regarding the STELLAR programs, and I mediate the reply to your question lies in the STELLAR programs where their discussions with regulators were around both trials independently, but I mediate everybody understands that a third of patients with F3 really accommodate F4, and a third of patients with F4 accommodate F3. So, if for specimen there was a situation where one trial was positive and one trial was negative, they would exist able to view at different subgroups of patients, but that would exist a completely unscripted discussion that would just depend on what the data looked fondness at that time.

Operator

Thank you for participating in today's question-and-answer session. I would now fondness to whirl the convoke back over to Sung Lee for any closing remarks.

Sung Lee -- Vice President of Investor Relations

Thank you, Cherie and thank you every sole for joining us today. They treasure your continued interest in Gilead, and the team here looks forward to providing you with updates on their future progress.

Operator

Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program. You may every sole disconnect, and accommodate a wonderful day.

Duration: 57 minutes

Call participants:

Sung Lee -- Vice President of Investor Relations

Robin Washington -- Executive Vice President and Chief pecuniary Officer

Laura Hamill -- Executive Vice President, Worldwide Commercial Operations

John McHutchison -- Chief Scientific Officer and Head of Research and Development

John Milligan -- President and Chief Executive Officer

Geoff Meacham -- Barclays -- Analyst

Brian Abrahams -- RBC Capital Markets -- Analyst

Michael Yee -- Jefferies -- Analyst

Matthew Harrison -- Morgan Stanley -- Analyst

Geoffrey Porges -- Leerink -- Analyst

Greg Harrison -- Citi -- Analyst

Umer Raffat -- Evercore -- Analyst

Alethia immature -- Cantor Fitzgerald -- Analyst

Phil Nadeau -- Cowen -- Analyst

Cory Kasimov -- JPMorgan -- Analyst

Terence Flynn -- Goldman Sachs -- Analyst

Ying Huang -- Bank of America Merrill Lynch -- Analyst

Steven Seedhouse -- Raymond James -- Analyst

More GILD analysis

Transcript powered by AlphaStreet

This article is a transcript of this conference convoke produced for The Motley Fool. While they strive for their absurd Best, there may exist errors, omissions, or inaccuracies in this transcript. As with every sole their articles, The Motley Fool does not assume any responsibility for your employ of this content, and they strongly hearten you to achieve your own research, including listening to the convoke yourself and reading the company's SEC filings. please espy their Terms and Conditions for additional details, including their Obligatory Capitalized Disclaimers of Liability.

More From The Motley Fool

Motley Fool Transcribers has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has the following options: long November 2018 $78 calls on Gilead Sciences. The Motley Fool has a disclosure policy.


Express, Inc. Announces Earnings Release Date, Conference convoke and Webcast for Fourth Quarter and Fiscal 2016 Results | killexams.com actual questions and Pass4sure dumps

COLUMBUS, Ohio--(BUSINESS WIRE)--Express, Inc. (NYSE: EXPR), a specialty retail apparel company, today announced that it will conduct a conference convoke to argue fourth quarter and fiscal year 2016 results on Wednesday, March 8, 2017, at 9:00 a.m. ET. Earlier that morning, the Company will issue a press release detailing those results. The conference convoke will exist hosted by David Kornberg, president and chief executive officer, Matthew Moellering, executive vice president and chief operating officer, and Perry Pericleous, senior vice president and chief pecuniary officer.

Investors and analysts interested in participating in the convoke are invited to dial (877) 705-6003 approximately ten minutes prior to the start of the call. The conference convoke will besides exist webcast live at: http://www.express.com/investor and remain available for 90 days. A telephone replay of this convoke will exist available at 12:00 p.m. ET on March 8, 2017, until 11:59 p.m. ET on March 15, 2017, and can exist accessed by dialing (844) 512-2921 and entering the replay pin number 13654883.

In addition, an investor presentation of fourth quarter and fiscal year 2016 results will exist available at: http://www.express.com/investor at approximately 7:00 a.m. ET on Wednesday, March 8, 2017.

About Express, Inc.:

Express is a specialty apparel and accessories retailer of women's and men's merchandise, targeting the 20 to 30- year-old customer. Express has more than 35 years of sustain offering a discrete combination of fashion and character for multiple lifestyle occasions at an attractive value addressing fashion needs across work, casual, jeanswear, and going-out occasions. The Company currently operates more than 650 retail and factory outlet stores, located primarily in high-traffic shopping malls, lifestyle centers, and street locations across the United States, Canada, and Puerto Rico. Express merchandise is besides available at franchise locations in Latin America. Express besides markets and sells its products through its e-commerce website, www.express.com, as well as on its mobile app.



Direct Download of over 5500 Certification Exams

3COM [8 Certification Exam(s) ]
AccessData [1 Certification Exam(s) ]
ACFE [1 Certification Exam(s) ]
ACI [3 Certification Exam(s) ]
Acme-Packet [1 Certification Exam(s) ]
ACSM [4 Certification Exam(s) ]
ACT [1 Certification Exam(s) ]
Admission-Tests [13 Certification Exam(s) ]
ADOBE [93 Certification Exam(s) ]
AFP [1 Certification Exam(s) ]
AICPA [2 Certification Exam(s) ]
AIIM [1 Certification Exam(s) ]
Alcatel-Lucent [13 Certification Exam(s) ]
Alfresco [1 Certification Exam(s) ]
Altiris [3 Certification Exam(s) ]
Amazon [2 Certification Exam(s) ]
American-College [2 Certification Exam(s) ]
Android [4 Certification Exam(s) ]
APA [1 Certification Exam(s) ]
APC [2 Certification Exam(s) ]
APICS [2 Certification Exam(s) ]
Apple [69 Certification Exam(s) ]
AppSense [1 Certification Exam(s) ]
APTUSC [1 Certification Exam(s) ]
Arizona-Education [1 Certification Exam(s) ]
ARM [1 Certification Exam(s) ]
Aruba [6 Certification Exam(s) ]
ASIS [2 Certification Exam(s) ]
ASQ [3 Certification Exam(s) ]
ASTQB [8 Certification Exam(s) ]
Autodesk [2 Certification Exam(s) ]
Avaya [96 Certification Exam(s) ]
AXELOS [1 Certification Exam(s) ]
Axis [1 Certification Exam(s) ]
Banking [1 Certification Exam(s) ]
BEA [5 Certification Exam(s) ]
BICSI [2 Certification Exam(s) ]
BlackBerry [17 Certification Exam(s) ]
BlueCoat [2 Certification Exam(s) ]
Brocade [4 Certification Exam(s) ]
Business-Objects [11 Certification Exam(s) ]
Business-Tests [4 Certification Exam(s) ]
CA-Technologies [21 Certification Exam(s) ]
Certification-Board [10 Certification Exam(s) ]
Certiport [3 Certification Exam(s) ]
CheckPoint [41 Certification Exam(s) ]
CIDQ [1 Certification Exam(s) ]
CIPS [4 Certification Exam(s) ]
Cisco [318 Certification Exam(s) ]
Citrix [47 Certification Exam(s) ]
CIW [18 Certification Exam(s) ]
Cloudera [10 Certification Exam(s) ]
Cognos [19 Certification Exam(s) ]
College-Board [2 Certification Exam(s) ]
CompTIA [76 Certification Exam(s) ]
ComputerAssociates [6 Certification Exam(s) ]
Consultant [2 Certification Exam(s) ]
Counselor [4 Certification Exam(s) ]
CPP-Institue [2 Certification Exam(s) ]
CPP-Institute [1 Certification Exam(s) ]
CSP [1 Certification Exam(s) ]
CWNA [1 Certification Exam(s) ]
CWNP [13 Certification Exam(s) ]
Dassault [2 Certification Exam(s) ]
DELL [9 Certification Exam(s) ]
DMI [1 Certification Exam(s) ]
DRI [1 Certification Exam(s) ]
ECCouncil [21 Certification Exam(s) ]
ECDL [1 Certification Exam(s) ]
EMC [129 Certification Exam(s) ]
Enterasys [13 Certification Exam(s) ]
Ericsson [5 Certification Exam(s) ]
ESPA [1 Certification Exam(s) ]
Esri [2 Certification Exam(s) ]
ExamExpress [15 Certification Exam(s) ]
Exin [40 Certification Exam(s) ]
ExtremeNetworks [3 Certification Exam(s) ]
F5-Networks [20 Certification Exam(s) ]
FCTC [2 Certification Exam(s) ]
Filemaker [9 Certification Exam(s) ]
Financial [36 Certification Exam(s) ]
Food [4 Certification Exam(s) ]
Fortinet [12 Certification Exam(s) ]
Foundry [6 Certification Exam(s) ]
FSMTB [1 Certification Exam(s) ]
Fujitsu [2 Certification Exam(s) ]
GAQM [9 Certification Exam(s) ]
Genesys [4 Certification Exam(s) ]
GIAC [15 Certification Exam(s) ]
Google [4 Certification Exam(s) ]
GuidanceSoftware [2 Certification Exam(s) ]
H3C [1 Certification Exam(s) ]
HDI [9 Certification Exam(s) ]
Healthcare [3 Certification Exam(s) ]
HIPAA [2 Certification Exam(s) ]
Hitachi [30 Certification Exam(s) ]
Hortonworks [4 Certification Exam(s) ]
Hospitality [2 Certification Exam(s) ]
HP [746 Certification Exam(s) ]
HR [4 Certification Exam(s) ]
HRCI [1 Certification Exam(s) ]
Huawei [21 Certification Exam(s) ]
Hyperion [10 Certification Exam(s) ]
IAAP [1 Certification Exam(s) ]
IAHCSMM [1 Certification Exam(s) ]
IBM [1530 Certification Exam(s) ]
IBQH [1 Certification Exam(s) ]
ICAI [1 Certification Exam(s) ]
ICDL [6 Certification Exam(s) ]
IEEE [1 Certification Exam(s) ]
IELTS [1 Certification Exam(s) ]
IFPUG [1 Certification Exam(s) ]
IIA [3 Certification Exam(s) ]
IIBA [2 Certification Exam(s) ]
IISFA [1 Certification Exam(s) ]
Intel [2 Certification Exam(s) ]
IQN [1 Certification Exam(s) ]
IRS [1 Certification Exam(s) ]
ISA [1 Certification Exam(s) ]
ISACA [4 Certification Exam(s) ]
ISC2 [6 Certification Exam(s) ]
ISEB [24 Certification Exam(s) ]
Isilon [4 Certification Exam(s) ]
ISM [6 Certification Exam(s) ]
iSQI [7 Certification Exam(s) ]
ITEC [1 Certification Exam(s) ]
Juniper [63 Certification Exam(s) ]
LEED [1 Certification Exam(s) ]
Legato [5 Certification Exam(s) ]
Liferay [1 Certification Exam(s) ]
Logical-Operations [1 Certification Exam(s) ]
Lotus [66 Certification Exam(s) ]
LPI [24 Certification Exam(s) ]
LSI [3 Certification Exam(s) ]
Magento [3 Certification Exam(s) ]
Maintenance [2 Certification Exam(s) ]
McAfee [8 Certification Exam(s) ]
McData [3 Certification Exam(s) ]
Medical [69 Certification Exam(s) ]
Microsoft [368 Certification Exam(s) ]
Mile2 [2 Certification Exam(s) ]
Military [1 Certification Exam(s) ]
Misc [1 Certification Exam(s) ]
Motorola [7 Certification Exam(s) ]
mySQL [4 Certification Exam(s) ]
NBSTSA [1 Certification Exam(s) ]
NCEES [2 Certification Exam(s) ]
NCIDQ [1 Certification Exam(s) ]
NCLEX [2 Certification Exam(s) ]
Network-General [12 Certification Exam(s) ]
NetworkAppliance [36 Certification Exam(s) ]
NI [1 Certification Exam(s) ]
NIELIT [1 Certification Exam(s) ]
Nokia [6 Certification Exam(s) ]
Nortel [130 Certification Exam(s) ]
Novell [37 Certification Exam(s) ]
OMG [10 Certification Exam(s) ]
Oracle [269 Certification Exam(s) ]
P&C [2 Certification Exam(s) ]
Palo-Alto [4 Certification Exam(s) ]
PARCC [1 Certification Exam(s) ]
PayPal [1 Certification Exam(s) ]
Pegasystems [11 Certification Exam(s) ]
PEOPLECERT [4 Certification Exam(s) ]
PMI [15 Certification Exam(s) ]
Polycom [2 Certification Exam(s) ]
PostgreSQL-CE [1 Certification Exam(s) ]
Prince2 [6 Certification Exam(s) ]
PRMIA [1 Certification Exam(s) ]
PsychCorp [1 Certification Exam(s) ]
PTCB [2 Certification Exam(s) ]
QAI [1 Certification Exam(s) ]
QlikView [1 Certification Exam(s) ]
Quality-Assurance [7 Certification Exam(s) ]
RACC [1 Certification Exam(s) ]
Real-Estate [1 Certification Exam(s) ]
RedHat [8 Certification Exam(s) ]
RES [5 Certification Exam(s) ]
Riverbed [8 Certification Exam(s) ]
RSA [15 Certification Exam(s) ]
Sair [8 Certification Exam(s) ]
Salesforce [5 Certification Exam(s) ]
SANS [1 Certification Exam(s) ]
SAP [98 Certification Exam(s) ]
SASInstitute [15 Certification Exam(s) ]
SAT [1 Certification Exam(s) ]
SCO [10 Certification Exam(s) ]
SCP [6 Certification Exam(s) ]
SDI [3 Certification Exam(s) ]
See-Beyond [1 Certification Exam(s) ]
Siemens [1 Certification Exam(s) ]
Snia [7 Certification Exam(s) ]
SOA [15 Certification Exam(s) ]
Social-Work-Board [4 Certification Exam(s) ]
SpringSource [1 Certification Exam(s) ]
SUN [63 Certification Exam(s) ]
SUSE [1 Certification Exam(s) ]
Sybase [17 Certification Exam(s) ]
Symantec [134 Certification Exam(s) ]
Teacher-Certification [4 Certification Exam(s) ]
The-Open-Group [8 Certification Exam(s) ]
TIA [3 Certification Exam(s) ]
Tibco [18 Certification Exam(s) ]
Trainers [3 Certification Exam(s) ]
Trend [1 Certification Exam(s) ]
TruSecure [1 Certification Exam(s) ]
USMLE [1 Certification Exam(s) ]
VCE [6 Certification Exam(s) ]
Veeam [2 Certification Exam(s) ]
Veritas [33 Certification Exam(s) ]
Vmware [58 Certification Exam(s) ]
Wonderlic [2 Certification Exam(s) ]
Worldatwork [2 Certification Exam(s) ]
XML-Master [3 Certification Exam(s) ]
Zend [6 Certification Exam(s) ]





References :


Dropmark : http://killexams.dropmark.com/367904/11794404
Wordpress : http://wp.me/p7SJ6L-1Hp
Dropmark-Text : http://killexams.dropmark.com/367904/12563882
Blogspot : http://killexamsbraindump.blogspot.com/2017/12/httpkillexamsbraindumpblogspotcom201712_15.html
RSS Feed : http://feeds.feedburner.com/EnsureYourSuccessWithThis920-130QuestionBank
Box.net : https://app.box.com/s/brtyf12yc39qzuc6xrpjhwlyzt5cgdss











Killexams 920-130 exams | Killexams 920-130 cert | Pass4Sure 920-130 questions | Pass4sure 920-130 | pass-guaratee 920-130 | best 920-130 test preparation | best 920-130 training guides | 920-130 examcollection | killexams | killexams 920-130 review | killexams 920-130 legit | kill 920-130 example | kill 920-130 example journalism | kill exams 920-130 reviews | kill exam ripoff report | review 920-130 | review 920-130 quizlet | review 920-130 login | review 920-130 archives | review 920-130 sheet | legitimate 920-130 | legit 920-130 | legitimacy 920-130 | legitimation 920-130 | legit 920-130 check | legitimate 920-130 program | legitimize 920-130 | legitimate 920-130 business | legitimate 920-130 definition | legit 920-130 site | legit online banking | legit 920-130 website | legitimacy 920-130 definition | >pass 4 sure | pass for sure | p4s | pass4sure certification | pass4sure exam | IT certification | IT Exam | 920-130 material provider | pass4sure login | pass4sure 920-130 exams | pass4sure 920-130 reviews | pass4sure aws | pass4sure 920-130 security | pass4sure coupon | pass4sure 920-130 dumps | pass4sure cissp | pass4sure 920-130 braindumps | pass4sure 920-130 test | pass4sure 920-130 torrent | pass4sure 920-130 download | pass4surekey | pass4sure cap | pass4sure free | examsoft | examsoft login | exams | exams free | examsolutions | exams4pilots | examsoft download | exams questions | examslocal | exams practice |



International Edition Textbooks

Save huge amounts of cash when you buy international edition textbooks from TEXTBOOKw.com. An international edition is a textbook that has been published outside of the US and can be drastically cheaper than the US edition.

** International edition textbooks save students an average of 50% over the prices offered at their college bookstores.

Highlights > Recent Additions
Showing Page 1 of 5
Operations & Process Management: Principles & Practice for Strategic ImpactOperations & Process Management: Principles & Practice for Strategic Impact
By Nigel Slack, Alistair Jones
Publisher : Pearson (Feb 2018)
ISBN10 : 129217613X
ISBN13 : 9781292176130
Our ISBN10 : 129217613X
Our ISBN13 : 9781292176130
Subject : Business & Economics
Price : $75.00
Computer Security: Principles and PracticeComputer Security: Principles and Practice
By William Stallings, Lawrie Brown
Publisher : Pearson (Aug 2017)
ISBN10 : 0134794109
ISBN13 : 9780134794105
Our ISBN10 : 1292220619
Our ISBN13 : 9781292220611
Subject : Computer Science & Technology
Price : $65.00
Urban EconomicsUrban Economics
By Arthur O’Sullivan
Publisher : McGraw-Hill (Jan 2018)
ISBN10 : 126046542X
ISBN13 : 9781260465426
Our ISBN10 : 1260084493
Our ISBN13 : 9781260084498
Subject : Business & Economics
Price : $39.00
Urban EconomicsUrban Economics
By Arthur O’Sullivan
Publisher : McGraw-Hill (Jan 2018)
ISBN10 : 0078021782
ISBN13 : 9780078021787
Our ISBN10 : 1260084493
Our ISBN13 : 9781260084498
Subject : Business & Economics
Price : $65.00
Understanding BusinessUnderstanding Business
By William G Nickels, James McHugh, Susan McHugh
Publisher : McGraw-Hill (Feb 2018)
ISBN10 : 126021110X
ISBN13 : 9781260211108
Our ISBN10 : 126009233X
Our ISBN13 : 9781260092332
Subject : Business & Economics
Price : $75.00
Understanding BusinessUnderstanding Business
By William Nickels, James McHugh, Susan McHugh
Publisher : McGraw-Hill (May 2018)
ISBN10 : 1260682137
ISBN13 : 9781260682137
Our ISBN10 : 126009233X
Our ISBN13 : 9781260092332
Subject : Business & Economics
Price : $80.00
Understanding BusinessUnderstanding Business
By William Nickels, James McHugh, Susan McHugh
Publisher : McGraw-Hill (Jan 2018)
ISBN10 : 1260277143
ISBN13 : 9781260277142
Our ISBN10 : 126009233X
Our ISBN13 : 9781260092332
Subject : Business & Economics
Price : $77.00
Understanding BusinessUnderstanding Business
By William Nickels, James McHugh, Susan McHugh
Publisher : McGraw-Hill (Jan 2018)
ISBN10 : 1259929434
ISBN13 : 9781259929434
Our ISBN10 : 126009233X
Our ISBN13 : 9781260092332
Subject : Business & Economics
Price : $76.00
920-130920-130
By Peter W. Cardon
Publisher : McGraw-Hill (Jan 2017)
ISBN10 : 1260128474
ISBN13 : 9781260128475
Our ISBN10 : 1259921883
Our ISBN13 : 9781259921889
Subject : Business & Economics, Communication & Media
Price : $39.00
920-130920-130
By Peter Cardon
Publisher : McGraw-Hill (Feb 2017)
ISBN10 : 1260147150
ISBN13 : 9781260147155
Our ISBN10 : 1259921883
Our ISBN13 : 9781259921889
Subject : Business & Economics, Communication & Media
Price : $64.00
Result Page : 1 2 3 4 5